Metagenomi Therapeutics, Inc. MGX
1.15
0.00
0.00%
as of 25 Sep
- Market cap
- $43.4M
- P/E
- 0.0×
Follow MGX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (60.61%) | (49.02%) | (44.67%) | (40.87%) |
+8 more TTM periods Free account |
|
| (41.91%) | (34.71%) | (32.20%) | (29.27%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(87.57%) | (64.47%) | (56.73%) | (50.96%) | |
Average Days of Receivables |
0.00 | 0.00 | 4.42 | 11.34 | |
Free Cash Flow per Share |
(2.28) | (2.33) | (2.40) | (2.47) | |
Free Cash Flow |
(85.80) | (87.50) | (89.43) | (92.41) | |
Capital Expenditures |
(0.31) | (0.27) | (0.54) | (0.79) | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(36.65%) | (31.38%) | (27.83%) | (25.27%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 32.28 | 39.91 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | (0.01) | |
Research and Development Expense of Revenue |
653.31% | 396.72% | 374.59% | 310.86% | |
Selling, General and Administrative Expense of Revenue |
188.27% | 118.76% | 106.27% | 87.62% | |
Share Based Compensation of Revenue |
77.60% | 51.39% | 47.02% | 40.67% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.91 | 1.02 | 1.01 | 1.03 | |
Depreciation/Fixed assets |
0.40 | 0.25 | 0.17 | 0.10 | |
Capex/Depreciation |
(0.08) | (0.10) | (0.26) | (0.58) | |
Revenue per Share |
0.36 | 0.59 | 0.68 | 0.83 | |
Operating CF per Share |
(2.27) | (2.32) | (2.39) | (2.45) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.02) | |
Capex to Sales |
0.02 | 0.01 | 0.02 | 0.03 | |
Net Profit Margin |
(689.20%) | (384.61%) | (348.54%) | (287.06%) |
Columns are period end dates